How to Get Belsomra (Suvorexant) in Texas

What Is Suvorexant and Why Does Access Matter in Texas?

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks wake-promoting orexin-A and orexin-B neuropeptides to promote sleep onset and maintenance. The FDA approved Belsomra in August 2014 for treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance in adults [1]. Unlike benzodiazepine receptor agonists, suvorexant does not act on GABA pathways.

Access in Texas carries specific wrinkles. The state permits telehealth prescribing of Schedule IV substances, but Texas Medicaid excludes Belsomra for insomnia. That gap pushes many Texans toward commercial insurance pathways or out-of-pocket payment. According to the Texas Health and Human Services Commission, the state's Medicaid formulary restricts suvorexant coverage to a narrow type 2 diabetes indication, leaving the 3.2 million Texas adults who report chronic insomnia symptoms (per CDC Behavioral Risk Factor data) without a public-payer route to this drug class.

The clinical rationale for pursuing suvorexant over older agents is supported by Herring et al. in The Lancet Neurology (2014), a phase 3 trial (N=1,021) demonstrating that suvorexant 20 mg reduced wake after sleep onset (WASO) by 22.7 minutes versus placebo at month 3, with sustained efficacy through 12 months of nightly use [2]. That durability matters for patients who have cycled through short-term Z-drug prescriptions.

Step-by-Step: Getting a Belsomra Prescription in Texas

The fastest path to a suvorexant prescription in Texas follows four steps: find a licensed prescriber, complete an insomnia evaluation, handle insurance logistics, and fill at a pharmacy.

Step 1: Choose a prescriber. Any Texas-licensed MD, DO, NP with prescriptive authority agreement, or PA with delegated prescriptive authority can prescribe Belsomra. The Texas Medical Board permits Schedule IV prescribing via telemedicine under TMB Rule 174, provided a valid patient-physician relationship is established. A first-visit telemedicine encounter satisfies this requirement for non-opioid Schedule IV drugs.

Step 2: Complete an insomnia evaluation. Prescribers typically assess sleep-wake patterns, rule out obstructive sleep apnea, review current medications, and screen for contraindications including narcolepsy, severe hepatic impairment, or concurrent use of strong CYP3A inhibitors (ketoconazole, clarithromycin). No specific lab panel is mandatory before prescribing, though some clinicians order a comprehensive metabolic panel and thyroid-stimulating hormone (TSH) to exclude metabolic causes of sleep disturbance.

Step 3: Handle insurance. This is where most delays occur. See the prior authorization section below.

Step 4: Fill the prescription. Any licensed Texas retail pharmacy can dispense Belsomra. Prescriptions must be transmitted electronically per the Texas Electronic Prescribing Act (SB 667), which mandates e-prescribing for all controlled substances.

Telehealth Prescribing Rules in Texas

Texas law permits licensed prescribers to initiate suvorexant via synchronous audio-video telemedicine visits. No prior in-person visit is required for Schedule IV controlled substances.

The Texas Medical Board's telemedicine rules, codified in 22 TAC §174, allow physicians to establish a practitioner-patient relationship through a real-time audiovisual encounter. The prescriber must be licensed in Texas or hold a telemedicine license issued by TMB. Audio-only telephone visits do not satisfy the standard for initial controlled-substance prescriptions.

For nurse practitioners, the Texas Board of Nursing requires a prescriptive authority agreement with a supervising physician. The agreement must explicitly authorize Schedule IV prescribing. NPs practicing under a prescriptive authority agreement may prescribe suvorexant via telehealth under the same synchronous audiovisual standard.

Refill visits can occur via audio-only telephone in some clinical settings, though individual practice policies vary. Most telehealth platforms serving Texas require the initial visit to be video-based, with follow-ups scheduled at 30 to 90 day intervals depending on treatment response.

Insurance Coverage and Prior Authorization

Commercial insurers in Texas generally cover Belsomra on a non-preferred brand tier with prior authorization. Texas Medicaid does not cover suvorexant for insomnia.

The prior authorization process for commercial plans typically requires documentation of the following:

1. Diagnosis confirmation. ICD-10 code G47.00 (insomnia, unspecified) or G47.01 (primary insomnia).
2. Step therapy failure. Most plans require documented trial and failure of, or contraindication to, at least one generic sleep agent. Common step-therapy drugs include zolpidem (generic Ambien), eszopiclone (generic Lunesta), and trazodone.
3. Duration and severity. Evidence that insomnia symptoms have persisted for at least 3 months and cause functional impairment.
4. Prescriber attestation. Statement that the patient does not have contraindications listed in the Belsomra prescribing information, including concurrent use of strong CYP3A inhibitors or narcolepsy [3].

Processing time ranges from 24 hours to 14 business days. Plans must issue a determination within the timeframe specified by the Texas Department of Insurance, which is 3 business days for standard requests and 72 hours for urgent requests.

For patients denied coverage, a Letter of Medical Necessity from the prescriber can support an appeal. The letter should reference the Herring et al. trial data showing sustained efficacy at 12 months [2] and note the patient's documented failure on generic alternatives.

Cost without insurance. Retail price for a 30-day supply of Belsomra 20 mg ranges from $380 to $480 at Texas pharmacies. Merck's savings card program can reduce copays to $40 to $75 per fill for commercially insured patients. GoodRx and similar discount platforms show Texas cash prices between $340 and $420 depending on zip code.

Texas Medicaid: Why Belsomra Isn't Covered for Insomnia

Texas Medicaid's Vendor Drug Program restricts suvorexant coverage to a type 2 diabetes indication. The insomnia indication is excluded from the preferred drug list.

This restriction reflects a utilization management decision, not a clinical safety concern. The Texas Health and Human Services Commission Pharmaceutical and Therapeutics Committee evaluates drugs based on comparative effectiveness, cost, and therapeutic alternatives. Because generic Z-drugs (zolpidem, eszopiclone) and low-cost sedating agents (trazodone, doxepin) are available, the committee has not added branded suvorexant for insomnia to the formulary.

Medicaid recipients in Texas who need a DORA-class drug may request a non-preferred drug authorization through their managed care organization. Approval rates for these requests are low without documentation of failure on at least two formulary alternatives. The American Academy of Sleep Medicine's 2017 clinical practice guideline lists suvorexant as a recommended treatment for sleep maintenance insomnia, which can support a non-preferred drug request [4].

503A Compounding Pharmacies in Texas

Licensed 503A compounding pharmacies in Texas can compound suvorexant preparations under specific conditions, though commercial Belsomra tablets remain the standard dispensing form.

The Texas State Board of Pharmacy oversees 503A compounding under Chapter 562 of the Texas Pharmacy Act. A 503A pharmacy may compound suvorexant only in response to a valid patient-specific prescription. Bulk compounding without individual prescriptions is prohibited under Texas law and FDA guidance on 503A facilities [5].

Texas requires sterile and non-sterile compounding pharmacies to hold appropriate licenses and undergo regular inspections. Patients considering a compounded suvorexant preparation should verify that the pharmacy holds a current Texas Class A or Class E pharmacy license and that suvorexant is not on the FDA's "Demonstrably Difficult to Compound" list. As of 2026, suvorexant does not appear on that list.

Compounded preparations may cost less than brand-name Belsomra, with reported prices of $90 to $180 for a 30-day supply depending on the compounding pharmacy. Shipping within Texas is permitted for 503A pharmacies licensed in the state.

Prescriber Types: MD vs. NP vs. PA in Texas

Three categories of Texas-licensed clinicians can prescribe suvorexant. Their prescriptive authority differs in supervision requirements but not in the drugs they can prescribe.

Physicians (MD/DO). Full independent prescriptive authority for all scheduled drugs. No supervision requirement. Can prescribe via telemedicine under TMB Rule 174.

Nurse Practitioners (NP). May prescribe Schedule IV controlled substances under a prescriptive authority agreement with a Texas-licensed physician. The Texas Board of Nursing requires the agreement to be site-specific. NPs with at least 4,000 hours of advanced practice experience may practice with a more flexible collaborative relationship.

Physician Assistants (PA). May prescribe Schedule IV drugs if delegated by their supervising physician. The prescriptive delegation agreement must be filed with the Texas Medical Board. PAs may prescribe up to a 90-day supply of Schedule IV substances per prescription.

All three prescriber types can conduct telemedicine visits for suvorexant. The critical requirement is that the prescriber holds an active Texas license and that the patient is physically located in Texas at the time of the encounter.

Clinical Considerations Before Starting Suvorexant

Prescribers in Texas follow the same clinical evaluation framework used nationally. The FDA-approved dosing starts at 10 mg taken within 30 minutes of bedtime, with at least 7 hours of planned sleep time remaining.

The 10 mg starting dose may be increased to 20 mg if 10 mg is tolerated but insufficiently effective. The Belsomra prescribing information warns against doses exceeding 20 mg due to dose-dependent increases in next-day somnolence and driving impairment [3].

Key contraindications include narcolepsy and concurrent use of strong CYP3A inhibitors. Caution applies in patients with moderate hepatic impairment (dose adjustment not established), compromised respiratory function, depression with suicidal ideation, or a history of complex sleep behaviors.

In the Herring et al. phase 3 trial, the most common adverse events with suvorexant 20 mg were somnolence (7% vs. 3% placebo), headache, and dizziness [2]. The trial enrolled adults aged 18 and older with DSM-IV primary insomnia, treated nightly for 12 months. Sleep efficiency (measured by polysomnography in a subset) improved by 6.4 percentage points versus placebo at month 1.

The American Academy of Sleep Medicine conditionally recommends suvorexant for sleep maintenance insomnia in adults, noting moderate-quality evidence for efficacy and an acceptable safety profile at approved doses [4].

Timeline: How Long Until You Receive Belsomra in Texas

From initial prescriber contact to medication in hand, Texas patients should expect 3 to 14 days depending on insurance status.

Cash-pay or approved insurance (no PA needed). Same-day or next-day fill at most retail pharmacies. Electronic prescribing is transmitted within minutes.

Commercial insurance with prior authorization. 3 to 7 business days for standard PA review. Some plans offer expedited review in 24 to 72 hours if the prescriber marks the request as urgent.

Denied PA with appeal. 14 to 30 days for a first-level appeal. Second-level external review through the Texas Department of Insurance can take an additional 15 to 30 days.

Compounding pharmacy. 3 to 7 days for preparation and shipping within Texas. Some compounding pharmacies require a consultation call before first fill.

Patients who need immediate treatment while awaiting PA approval may ask their prescriber for a short-term bridge prescription of a generic alternative or request a manufacturer bridge supply through the Merck patient assistance program.

Transferring a Belsomra Prescription to Texas

Patients relocating to Texas from another state can transfer an existing suvorexant prescription to a Texas pharmacy under specific conditions.

Schedule IV prescriptions may be transferred between pharmacies one time only under DEA regulations (21 CFR 1306.26). The transferring and receiving pharmacies must both maintain electronic records of the transfer. Texas pharmacies participating in a shared real-time database system (such as pharmacies within the same chain) may transfer Schedule IV prescriptions electronically.

The prescriber's DEA number and state license must be valid. If the original prescriber is not licensed in Texas, the patient will need to establish care with a Texas-licensed provider for refills beyond the transferred prescription. A single telehealth visit is sufficient to establish this new prescriber relationship.